TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23679896

Group type: EXPERIMENTAL
Intervention: briakinumab
Number of subjects: 1465

Group type: EXPERIMENTAL
Intervention: briakinumab every 4 weeks
Number of subjects: 1465

Group type: EXPERIMENTAL
Intervention: briakinumab every 12 weeks
Number of subjects: 1465

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1465
Study: 21983050

Group type: EXPERIMENTAL
Intervention: 60-min walking on the treadmill (exercise trial; EX)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Seated rest (control trial; CON)
Number of subjects: 27
Study: 19836898

Group type: EXPERIMENTAL
Intervention: Cortisol (50mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18041488

Group type: EXPERIMENTAL
Intervention: Doxepin 3 mg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Doxepin 6 mg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Doxepin 1 mg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 15506578

Group type: EXPERIMENTAL
Intervention: Diagnoses for inhalational anthrax
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Fatal cases of inhalational anthrax
Number of subjects: 665
Study: 11467270

Group type: EXPERIMENTAL
Intervention: Both interventions (risk factor checklist and training video)
Number of subjects: 50

Group type: COMPARATOR
Intervention: One intervention (either checklist or training video)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 50
Study: 9733365

Group type: EXPERIMENTAL
Intervention: Moxonidine (0.4 mg/day; 1 month)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 0
Study: 8056186

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control treatment (CT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 18
Study: 2498619

Group type: EXPERIMENTAL
Intervention: Silicone vaginal rings releasing 7 micrograms/24 h of 17 beta‐oestradiol (E2)
Number of subjects: 2
Study: 790888

Group type: EXPERIMENTAL
Intervention: Etidocaine 1%
Number of subjects: 45

Group type: COMPARATOR
Intervention: Mepivacaine 1%
Number of subjects: 45
Study: 31541517

Group type: EXPERIMENTAL
Intervention: Short MDIs (6 or 8 mm long)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard MDIs (10-14 mm long)
Number of subjects: 63
Study: 29726939

Group type: EXPERIMENTAL
Intervention: Ustekinumab 6 mg/kg
Number of subjects: 1756

Group type: EXPERIMENTAL
Intervention: Ustekinumab 130 mg
Number of subjects: 1756

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1756

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg every 12 weeks (q12w)
Number of subjects: 1756

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg every 8 weeks (q8w)
Number of subjects: 1756

Group type: EXPERIMENTAL
Intervention: Ustekinumab (all doses)
Number of subjects: 1756
Study: 27266771

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural psychotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 60
Study: 24884910

Group type: EXPERIMENTAL
Intervention: Unidas intervention
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 89
Study: 22840987

Group type: EXPERIMENTAL
Intervention: PRGF-Endoret
Number of subjects: 176

Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA)
Number of subjects: 176
Study: 19725852

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography to evaluate myocardial viability before CRT implantation
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Presence of MR in patients with acute response
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination of MR presence and viability in the region of the pacing lead
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Viability in the region of the pacing lead
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Presence of MR
Number of subjects: 51
Study: 18727339

Group type: EXPERIMENTAL
Intervention: Warm compresses applied to the injection site before self-injection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual methods of injection preparation
Number of subjects: 50
Study: 15715686

Group type: EXPERIMENTAL
Intervention: Vitamin B12 injections
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 12870422

Group type: EXPERIMENTAL
Intervention: Eating Disorder Inventory (EDI-2)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Cronbach's alpha for EDI-2 subscales
Number of subjects: 2
Study: 10929907

Group type: EXPERIMENTAL
Intervention: Gallstone recurrence patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Patients without gallstone recurrence
Number of subjects: 33

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 33
Study: 8672354

Group type: EXPERIMENTAL
Intervention: Colloid priming (2.4% modified fluid gelatin, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Crystalloid priming (n = 10)
Number of subjects: 20
Study: 1891561

Group type: EXPERIMENTAL
Intervention: Cognitive function assessment post coronary artery bypass surgery
Number of subjects: 104
Study: 6299982

Group type: EXPERIMENTAL
Intervention: 0.5 mg terbutaline subcutaneously
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 5 mg terbutaline orally
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 14
Study: 31864383

Group type: EXPERIMENTAL
Intervention: Cool Kids Anxiety Program - Social Enhanced (CK-E)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Generic G-CBT program for anxiety disorders
Number of subjects: 96
Study: 29310899

Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg plus Rilpivirine 25 mg
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Current ART regimen (CAR)
Number of subjects: 1028
Study: 23754205

Group type: EXPERIMENTAL
Intervention: Metronidazole gel (3% w/v)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metronidazole solution (0.5% w/v)
Number of subjects: 20
Study: 22226343

Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 5 mg (bipolar disorder)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 10 mg (bipolar disorder)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20145598

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 0
Study: 16616147

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1800 mg/day
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 15923251

Group type: EXPERIMENTAL
Intervention: WLB+AFB
Number of subjects: 1173

Group type: COMPARATOR
Intervention: WLB
Number of subjects: 1173
Study: 12405366

Group type: EXPERIMENTAL
Intervention: Intrathecal drug therapy (IDT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional pain therapy (CPT)
Number of subjects: 67
Study: 10211272

Group type: EXPERIMENTAL
Intervention: Structured teaching technique (the silent run through)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (students taught at another hospital)
Number of subjects: 0
Study: 7840079

Group type: EXPERIMENTAL
Intervention: Biotin supplementation (10 mg/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2965140

Group type: EXPERIMENTAL
Intervention: Clenbuterol (0.75 micrograms/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Procaterol (1.5 micrograms/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29996800

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.5 g daily in two divided doses
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC) given intravenously as a monthly pulse
Number of subjects: 42
Study: 27804272

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 24147994

Group type: EXPERIMENTAL
Intervention: Mixed drilling/piezoelectric osteotomy (test group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional drilling (control group)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study: 22130403

Group type: EXPERIMENTAL
Intervention: Front Crawl (FC)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Backstroke (BK)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Breaststroke (BR)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Butterfly (FLY)
Number of subjects: 11
Study: 20442386

Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg for weight 18-35.9 kg or 500 mg for weight >= 36 kg) 3 days per week for 168 days
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 260
Study: 18403672

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg qd) plus Formoterol (12 microg bid)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Salmeterol (50 microg bid) plus Fluticasone (500 microg bid)
Number of subjects: 605
Study: 19406291

Group type: EXPERIMENTAL
Intervention: Sertraline (daily oral doses starting at 25mg, increasing to therapeutic levels up to 200mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sertraline and Placebo (both groups)
Number of subjects: 52
Study: 16586190

Group type: EXPERIMENTAL
Intervention: Gabapentin (300 mg to 3,600 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11311964

Group type: EXPERIMENTAL
Intervention: Gliclazide (80-240 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glibenclamide (5-15 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 9
Study: 8985076

Group type: EXPERIMENTAL
Intervention: Combined regional/general anesthesia with intraoperative epidural catheter anesthesia using Bupivacaine and postoperative epidural morphine
Number of subjects: 39

Group type: COMPARATOR
Intervention: General anesthesia with postoperative patient-controlled intravenous morphine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups (epidural and general anesthesia)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Patients with operative times greater than 5 hours
Number of subjects: 39
Study: 8501777

Group type: EXPERIMENTAL
Intervention: Orange juice (1.2 l. per day, containing 60 mEq. potassium and 190 mEq. citrate)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Potassium citrate (60 mEq. per day)
Number of subjects: 11
Study: 3630312

Group type: EXPERIMENTAL
Intervention: sublingual nifedipine 20 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: intravenous nifedipine 1 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 11775718

Group type: EXPERIMENTAL
Intervention: Bereavement Group Postvention (BGP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Social Group Postvention (SGP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined BGP and SGP
Number of subjects: 60
Study: 30611715

Group type: EXPERIMENTAL
Intervention: Psychoeducative intervention (25-min session)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 352
Study: 29161549

Group type: EXPERIMENTAL
Intervention: Ultrasound guided caudal block (Group U, n=68)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Conventional caudal block (Group C, n=66)
Number of subjects: 134
Study: 27233239

Group type: EXPERIMENTAL
Intervention: Vernakalant (3 mg/kg infusion over 10 min, followed by 2 mg/kg if AF not terminated)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 217
Study: 25280032

Group type: EXPERIMENTAL
Intervention: Pidotimod treatment for 30 days
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 157
Study: 22371457

Group type: EXPERIMENTAL
Intervention: Active video games
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactive video games
Number of subjects: 0
Study: 19775705

Group type: EXPERIMENTAL
Intervention: Skeletonized internal thoracic artery harvesting
Number of subjects: 41

Group type: COMPARATOR
Intervention: Pedicled internal thoracic artery harvesting
Number of subjects: 41
Study: 17369518

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) combined with task-specific upper extremity rehabilitation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group receiving task-specific therapy alone
Number of subjects: 15
Study: 14982768

Group type: EXPERIMENTAL
Intervention: Posaconazole with Mylanta under fasting conditions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Posaconazole with Mylanta under nonfasting conditions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Posaconazole with high-fat breakfast
Number of subjects: 12

Group type: COMPARATOR
Intervention: Posaconazole alone under fasting conditions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Posaconazole alone under nonfasting conditions
Number of subjects: 12
Study: 12003471

Group type: EXPERIMENTAL
Intervention: High threat condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low threat condition
Number of subjects: 0
Study: 9988543

Group type: EXPERIMENTAL
Intervention: Estrogen receptor status positive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progesterone receptor status positive
Number of subjects: 0
Study: 7859244

Group type: EXPERIMENTAL
Intervention: Quinapril (10 mg QD to 20 mg QD, titrated based on blood pressure response)
Number of subjects: 3742

Group type: EXPERIMENTAL
Intervention: Quinapril (part of antihypertensive regimen)
Number of subjects: 3742

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 3742
Study: 2814211

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 29
Study: 30895321

Group type: EXPERIMENTAL
Intervention: E+/E+ (ergot alkaloid exposure during both MID and LATE gestation)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: E-/E+ (ergot alkaloid exposure switched from E- to E+ during LATE gestation)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: E+/E- (ergot alkaloid exposure only during MID gestation)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: E+ (ergot alkaloid exposure during LATE gestation)
Number of subjects: 36
Study: 28879792

Group type: EXPERIMENTAL
Intervention: Naproxen (750 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26245919

Group type: EXPERIMENTAL
Intervention: Self-expanding nitinol stenting
Number of subjects: 92

Group type: COMPARATOR
Intervention: PTA with bailout stenting
Number of subjects: 92
Study: 23481908

Group type: EXPERIMENTAL
Intervention: CRT with pre‐determined optimal AVD
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nominal AV delay with AAI pacing
Number of subjects: 25
Study: 22088520

Group type: COMPARATOR
Intervention: Tirofiban with unfractionated heparin (UFH)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tirofiban with dalteparin
Number of subjects: 120
Study: 18157558

Group type: EXPERIMENTAL
Intervention: 10% Isomalt solutions rinsed for 5 minutes daily
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 10% Isomalt additions to re- or demineralizing solutions
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 10% Isomalt containing toothpaste brushed three times daily
Number of subjects: 2
Study: 16864741

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 7080

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 7080
Study: 12588772

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg (twice daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 10567042

Group type: EXPERIMENTAL
Intervention: CFS-No Psych group
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CFS-Psych group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 39
Study: 8720318

Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg t.i.d. over 5 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg o.d. over 3 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 12
Study: 1770275

Group type: EXPERIMENTAL
Intervention: Gonadotropin releasing hormone agonist (GNRHa), Buserelin, prior to and during induction of ovulation by hMG (Group I‐‐long protocol)
Number of subjects: 54

Group type: COMPARATOR
Intervention: GnRHa starting on the first day of the cycle together with induction of ovulation by hMG (Group II‐‐short protocol)
Number of subjects: 54
Study: 6889803

Group type: EXPERIMENTAL
Intervention: Oxymetazoline hydrochloride
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30448180

Group type: EXPERIMENTAL
Intervention: MiSight® contact lenses (CLs)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Single vision spectacles (SV)
Number of subjects: 74
Study: 28008174

Group type: EXPERIMENTAL
Intervention: Upfront autologous transplant (ASCT)
Number of subjects: 529
Study: 26633163

Group type: EXPERIMENTAL
Intervention: Top tertile of dietary glycemic index (GI)
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Top tertile of dietary glycemic load (GL)
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Repeated measures of dietary GI/GL
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Women with obesity or diabetes
Number of subjects: 4010
Study: 25148839

Group type: EXPERIMENTAL
Intervention: Individualized, multimodal exercise intervention (cardiorespiratory, flexibility, balance, and muscular strength training) 3 days per week for 3 months
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Individualized, multimodal exercise intervention
Number of subjects: 319
Study: 21798872

Group type: EXPERIMENTAL
Intervention: Repeated antenatal corticosteroids
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 19058133

Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa/entacapone (LCE) 100/25/200
Number of subjects: 423

Group type: COMPARATOR
Intervention: levodopa/carbidopa (LC) 100/25
Number of subjects: 423
Study: 17894339

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 69

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 69
Study: 16189630

Group type: EXPERIMENTAL
Intervention: Kremezin (oral carbonaceous adsorbent) paired with conventional treatment (antihypertensive therapy and low-protein diet)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Conventional treatment (antihypertensive therapy and low-protein diet) alone
Number of subjects: 450
Study: 12202465

Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg or more)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg or more)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg or greater)
Number of subjects: 11
Study: 9036798

Group type: EXPERIMENTAL
Intervention: Low-dose cidofovir (5 mg/kg once weekly for 2 weeks, then 3 mg/kg once every 2 weeks)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-dose cidofovir (5 mg/kg once weekly for 2 weeks, then 5 mg/kg once every 2 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Deferral group (treatment deferred until retinitis progressed)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Deferral group
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Low-dose cidofovir group
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-dose cidofovir group
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cidofovir recipients
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 64
Study: 7621149

Group type: EXPERIMENTAL
Intervention: Bag-valve-mask (BVM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manually triggered oxygen powered breathing device (MTBD)
Number of subjects: 30
Study: 3282815

Group type: EXPERIMENTAL
Intervention: Preoperative plus postoperative irradiation
Number of subjects: 364

Group type: COMPARATOR
Intervention: Postoperative irradiation alone
Number of subjects: 364
Study: 31728742

Group type: EXPERIMENTAL
Intervention: Analytic priming task
Number of subjects: 178

Group type: COMPARATOR
Intervention: Neutral priming task
Number of subjects: 178
Study: 31181249

Group type: EXPERIMENTAL
Intervention: Infant Feeding Beliefs Questionnaire (IFBQ)
Number of subjects: 803
Study: 27558098

Group type: EXPERIMENTAL
Intervention: Ponesimod regimen A (incremental dose increase from 2 to 20 mg in 9 steps)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ponesimod regimen B (10 mg for 7 days followed by a single-dose administration of 20 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ponesimod regimen A
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ponesimod regimen B
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ponesimod (both regimens)
Number of subjects: 32
Study: 25566560

Group type: EXPERIMENTAL
Intervention: Surgery with ring retractor
Number of subjects: 50

Group type: COMPARATOR
Intervention: Surgery without ring retractor (control)
Number of subjects: 50
Study: 23705963

Group type: EXPERIMENTAL
Intervention: Brief Qigong-based stress reduction program (BQSRP) for 4 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 50
Study: 21341919

Group type: EXPERIMENTAL
Intervention: Galantamine (8 mg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 19794998

Group type: EXPERIMENTAL
Intervention: Labor Assister (Baidy M‐420/Curexo, Inc., Seoul, Korea) with standard care
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 123
Study: 17124721

Group type: EXPERIMENTAL
Intervention: 1 mg DiaPep277
Number of subjects: 30

Group type: COMPARATOR
Intervention: 40 mg mannitol (placebo)
Number of subjects: 30
Study: 14727273

Group type: EXPERIMENTAL
Intervention: 1.5 mL hyperbaric bupivacaine 0.5% (7.5 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 4.2 mL hypobaric bupivacaine 0.18% (7.5 mg)
Number of subjects: 50